Singla Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.50 M
- Paid Up Capital ₹ 1.39 M
- Company Age 27 Year, 11 Months
- Last Filing with ROC 31 Mar 2024
- Satisfied Charges ₹ 2.00 M
About Singla Pharmaceuticals
Singla Pharmaceuticals Private Limited (SPPL) is a Private Limited Indian Non-Government Company incorporated in India on 19 February 1997 and has a history of 27 years and 11 months. Its registered office is in Punjab, Punjab.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.50 M and a paid-up capital of Rs 1.39 M.
The company has closed loans amounting to ₹2.00 M, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Sangeeta Singla, Sneh Lata, and Rajan Singla serve as directors at the Company.
Company Details
- Location Punjab, Punjab
-
Telephone
+91-XXXXXXXXXX
- Email Address
-
Website
-
-
Social Media
-
Corporate Identity Details
-
CIN/LLPIN
U24230PB1997PTC019467
-
Company No.
019467
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
19 Feb 1997
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Chandigarh
Industry
Who are the key members and board of directors at Singla Pharmaceuticals?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sangeeta Singla
|
Director | 19-Feb-1997 | Current |
|
Sneh Lata
|
Director | 19-Feb-1997 | Current |
|
Rajan Singla
|
Director | 19-Feb-1997 | Current |
Financial Performance of Singla Pharmaceuticals.
Singla Pharmaceuticals Private Limited, for the financial year ended 2017, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Singla Pharmaceuticals?
In 2017, Singla Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹0
₹2.00 M
Charges Breakdown by Lending Institutions
- State Bank Of India : 0.20 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 01 May 2008 | State Bank Of India | ₹2.00 M | Satisfied |
How Many Employees Work at Singla Pharmaceuticals?
Unlock and access historical data on people associated with Singla Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Singla Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Singla Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.